Dianthus Therapeutics, Inc. (DNTH)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$76.78-2.23%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Dianthus Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	358,620
EPS	—	-1.071
Annual ending 2026-12-31
Revenue	—	1.88M
EPS	—	-3.79
Annual ending 2027-12-31
Revenue	—	2.03M
EPS	—	-4.573

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Early GO decision for CAPTIVATE Part A maintained	Dianthus aims for an early GO decision on CAPTIVATE Part A, showing progress with a 95.5% score.	Intact	Early GO decision progress score falls below 95%	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Management announced an early GO decision for CAPTIVATE Part A in Q1 2026 after achieving 20 confirmed responders with fewer than 40 participants completing Part A. The Q2 interim analysis showed a 75% response rate, exceeding the 50% target, indicating delivery on this milestone. Delivery assessment Oct 24, 2026
EPS reaches at least $0.85 by June 2026	The company guides EPS of $0.85 for June 2026, signaling potential profitability.	Broken	EPS falls below $0.85 by June 2026	Diluted EPS: $-0.90 per share FY2026-Q2; GAAP. Published target: >=0.85 USD_PER_SHARE. Same fiscal period as the stored target. Source published Aug 4, 2026-0.9 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 3aeb7b13-1606-477c-b610-849ccdbd3e74. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Management announced an early GO decision for CAPTIVATE Part A in Q1 2026 after achieving 20 confirmed responders with fewer than 40 participants completing Part A. The Q2 interim analysis showed a 75% response rate, exceeding the 50% target, indicating delivery on this milestone. Delivery assessment Oct 24, 2026
Revenue decline moderates from -64% expected	A supporting condition in Dianthus Therapeutics, Inc.'s published investment case. The stated target is Revenue decline less than -30% YoY.	Intact	Revenue decline exceeds -30% YoY in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-4.57

$-4.48 → $-4.57 · observed estimates

FY2027 revenue$0.00B

$0.00B → $0.00B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-4.48	$1,819,273	9 / 9
2026-07-25	$-4.65	$1,585,330	9 / 12
2026-07-26	$-4.65	$1,585,330	9 / 12
2026-07-27	$-4.65	$1,585,330	9 / 12
2026-07-28	$-4.65	$1,585,330	9 / 12
2026-07-29	$-4.48	$1,819,273	9 / 9
2026-07-30	$-4.65	$1,585,330	9 / 12
2026-07-31	$-4.65	$1,585,330	9 / 12
2026-08-01	$-4.48	$1,819,273	9 / 9
2026-08-02	$-4.65	$1,585,330	9 / 12
2026-08-03	$-4.65	$1,585,330	9 / 12
2026-08-04	$-4.65	$1,585,330	9 / 12
2026-08-05	$-4.48	$1,819,273	9 / 9
2026-08-06	$-4.48	$1,819,273	9 / 9
2026-08-07	$-4.63	$2,035,917	9 / 8
2026-08-08	$-4.65	$2,059,500	9 / 10
2026-08-09	$-4.65	$2,059,500	9 / 10
2026-08-10	$-4.65	$2,059,500	9 / 10
2026-08-11	$-4.74	$2,059,500	9 / 10
2026-08-12	$-4.74	$1,716,250	9 / 12
2026-08-13	$-4.63	$2,035,917	9 / 8
2026-08-14	$-4.63	$2,035,917	9 / 8
2026-08-15	$-4.63	$2,035,917	9 / 8
2026-08-16	$-4.63	$2,035,917	9 / 8
2026-08-17	$-4.63	$2,035,917	9 / 8
2026-08-18	$-4.63	$2,035,917	9 / 8
2026-08-19	$-4.63	$2,035,917	9 / 8
2026-08-20	$-4.65	$2,035,917	9 / 9
2026-08-21	$-4.65	$2,035,917	9 / 9
2026-08-22	$-4.65	$2,035,917	9 / 9
2026-08-23	$-4.65	$2,035,917	9 / 9
2026-08-24	$-4.65	$2,035,917	9 / 9
2026-08-25	$-4.65	$2,035,917	9 / 9
2026-08-26	$-4.65	$2,035,917	9 / 9
2026-08-27	$-4.65	$2,035,917	9 / 9
2026-08-28	$-4.65	$2,035,917	9 / 9
2026-08-29	$-4.65	$2,035,917	9 / 9
2026-08-30	$-4.65	$2,035,917	9 / 9
2026-08-31	$-4.65	$2,035,917	9 / 9
2026-09-01	$-4.65	$2,035,917	9 / 9
2026-09-02	$-4.65	$2,035,917	9 / 9
2026-09-03	$-4.65	$2,035,917	9 / 9
2026-09-04	$-4.65	$2,035,917	9 / 9
2026-09-05	$-4.65	$2,035,917	9 / 9
2026-09-06	$-4.57	$2,029,766	10 / 9
2026-09-07	$-4.57	$2,029,766	10 / 9
2026-09-08	$-4.57	$2,029,766	10 / 9
2026-09-09	$-4.57	$2,029,766	10 / 9
2026-09-10	$-4.57	$2,029,766	10 / 9
2026-09-11	$-4.57	$2,029,766	10 / 9
2026-09-12	$-4.57	$2,029,766	10 / 9
2026-09-13	$-4.57	$2,027,639	10 / 10
2026-09-14	$-4.57	$2,027,639	10 / 10
2026-09-15	$-4.57	$2,027,639	10 / 10
2026-09-16	$-4.57	$2,027,639	11 / 10
2026-09-17	$-4.57	$2,027,639	11 / 10
2026-09-18	$-4.57	$2,027,639	11 / 10
2026-09-19	$-4.57	$2,027,639	11 / 10
2026-09-20	$-4.57	$2,027,639	11 / 10
2026-09-21	$-4.57	$2,027,639	11 / 10
2026-09-22	$-4.57	$2,027,639	11 / 10
2026-09-23	$-4.57	$2,027,639	11 / 10
2026-09-24	$-4.57	$2,027,639	11 / 10
2026-09-25	$-4.57	$2,027,639	11 / 10
2026-09-26	$-4.57	$2,027,639	11 / 10
2026-09-27	$-4.57	$2,027,639	11 / 10
2026-09-28	$-4.57	$2,027,639	11 / 10
2026-09-29	$-4.57	$2,027,639	11 / 10
2026-09-30	$-4.57	$2,027,639	11 / 10
2026-10-01	$-4.57	$2,027,639	11 / 10
2026-10-02	$-4.57	$2,027,639	11 / 10
2026-10-03	$-4.57	$2,027,639	11 / 10
2026-10-04	$-4.57	$2,027,639	11 / 10
2026-10-05	$-4.57	$2,027,639	11 / 10
2026-10-06	$-4.57	$2,027,639	11 / 10
2026-10-07	$-4.57	$2,027,639	11 / 10
2026-10-08	$-4.57	$2,027,639	11 / 10
2026-10-09	$-4.57	$2,027,639	11 / 10
2026-10-10	$-4.57	$2,027,639	11 / 10
2026-10-11	$-4.57	$2,027,639	11 / 10
2026-10-12	$-4.57	$2,027,639	11 / 10
2026-10-13	$-4.57	$2,027,639	11 / 10
2026-10-14	$-4.57	$2,027,639	11 / 10
2026-10-15	$-4.57	$2,027,639	11 / 10
2026-10-16	$-4.57	$2,027,639	11 / 10
2026-10-17	$-4.57	$2,027,639	11 / 10
2026-10-18	$-4.57	$2,027,639	11 / 10
2026-10-19	$-4.57	$2,027,639	11 / 10
2026-10-20	$-4.57	$2,027,639	11 / 10
2026-10-21	$-4.57	$2,027,639	11 / 10
2026-10-22	$-4.57	$2,027,639	11 / 10
2026-10-23	$-4.57	$2,027,639	11 / 10
2026-10-24	$-4.57	$2,027,639	11 / 10

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	16	0	0
2026-06-01	15	0	0
2026-07-01	15	0	0
2026-08-01	15	0	0
2026-09-01	17	0	0
2026-10-01	17	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 17 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Early GO decision for CAPTIVATE Part A maintainedDirect metric needs a verified mapping
EPS reaches at least $0.85 by June 2026Published status: Broken
Revenue decline moderates from -64% expectedDirect metric needs a verified mapping

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.0%Typical daily move · historical

Downside history

-37.8%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Dianthus Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is speculative growth, centered on clinical programs rather than established revenue. The long-term thesis is in a watch state: management has met the EMERGE trial start milestone, while the overall signal has shifted from mildly favorable to mixed.

What's priced into Dianthus Therapeutics, Inc.

The valuation model indicates a premium versus peers, with optionality driving the gap, but confidence in that assessment is low. The expectations gap is meaningful, and the priced-in tag is unjustified, so the evidence does not support a clear claim that current expectations are well grounded.

What the fundamentals likely do

Near term, financial performance is weak and the company is loss-making, with an elevated risk of missing expectations in a high-miss-rate industry. Over the multi-year view, progress depends on clinical execution: EMERGE began on schedule, CAPTIVATE Part B remains targeted for guidance by year-end 2026, and DNTH212 studies are ongoing.

What Dianthus Therapeutics, Inc. hinges on

The next guidance update is a key near-term swing factor, as a cut would be a meaningful negative. The longer-term case depends on trial progress, including CAPTIVATE Part B guidance and results from EMERGE expected in the second half of 2028. Healthcare sector momentum could support the backdrop, while weakening jobs data could raise recession concerns.